



Pharmaceutical Impurities: From Unwanted Chemicals to Critical Quality Attributes

Gustavo HR*

Department of Pharmaceutical Sciences, Federal University of Ouro Preto, Brazil

***Corresponding author:** Gustavo Henrique Ribeiro, Department of Pharmaceutical Sciences, Federal University of Ouro Preto, Brazil

Commentary

Volume 10 Issue 1

Received Date: January 08, 2026

Published Date: February 03, 2026

Abstract

Pharmaceutical impurities are unavoidable chemical components that can arise during synthesis, manufacturing, storage, or degradation of drug substances and products. Although traditionally regarded as unwanted substances requiring removal, impurities can provide important information about chemical stability, manufacturing processes, formulation behavior, and potential safety risks. Advances in analytical chemistry have significantly improved the detection and characterization of impurities, allowing even low-level components to be identified and monitored. Impurity assessment is therefore not simply a quality-control activity but an important part of pharmaceutical development. Understanding the origin, chemical structure, formation pathways, and potential biological significance of impurities can support better process design and more reliable drug products. This Commentary highlights the importance of impurity profiling from both medicinal and analytical chemistry perspectives and discusses how impurity control can contribute to pharmaceutical quality, safety, and consistency.

Keywords: Pharmaceutical Impurities; Impurity Profiling; Analytical Chemistry; Drug Quality; Degradation Products; Process Impurities; Pharmaceutical Safety; Quality Control

Commentary

The quality of a pharmaceutical product depends not only on the identity and potency of its active pharmaceutical ingredient (API) but also on the presence and control of substances that accompany the drug during manufacturing and storage. Pharmaceutical impurities may originate from starting materials, intermediates, reagents, catalysts, solvents, manufacturing processes, degradation reactions, or interactions with excipients. Although these components are generally present at low concentrations, their potential influence on product quality and safety makes impurity assessment an important aspect of pharmaceutical development [1,2].

Impurities are often viewed simply as unwanted chemicals that must be minimized. However, this perspective

does not fully reflect their scientific importance. The type and amount of impurities can provide valuable information about the chemical behavior of a drug substance. For example, the formation of a particular degradation product may indicate susceptibility to oxidation, hydrolysis, photochemical transformation, or other chemical processes. Understanding these pathways can therefore help researchers improve formulation and storage conditions.

From an **analytical chemistry** perspective, impurity profiling involves the detection, separation, identification, and quantification of chemical components present alongside the drug substance. Modern chromatographic and spectrometric techniques have substantially improved the ability to detect impurities at very low concentrations. High-performance liquid chromatography, gas chromatography, liquid chromatography-mass spectrometry, and nuclear magnetic

resonance spectroscopy can provide complementary information for impurity characterization [3,4].

The importance of analytical sensitivity should not, however, be separated from analytical relevance. Detecting an impurity does not automatically establish that it represents a significant safety concern. Its chemical structure, concentration, toxicity, exposure, and potential biological activity must also be considered. Consequently, impurity assessment requires both reliable analytical measurement and appropriate scientific interpretation.

Process-related impurities represent one major category. These substances may originate from starting materials, synthetic intermediates, reagents, catalysts, or reaction by-products. Their presence can be influenced by reaction conditions, purification efficiency, raw-material quality, and manufacturing processes. Understanding their formation pathways can help chemists optimize synthetic procedures and improve the consistency of pharmaceutical production [1,5].

Another important category consists of **degradation products**. Drug molecules can undergo chemical transformation during manufacturing, formulation, storage, or exposure to environmental conditions. Temperature, humidity, oxygen, light, and pH may contribute to degradation. The resulting products may differ substantially from the parent compound in terms of chemical and biological properties. Stability studies and appropriate analytical methods are therefore necessary to understand the degradation behavior of pharmaceutical substances [2,6].

Particular attention should be given to **potentially toxic or reactive impurities**. Some chemical structures may raise concerns because of their potential to interact with biological macromolecules or produce adverse biological effects. Genotoxic impurities are especially important because even low-level exposure may require careful assessment. Identifying structural features associated with potential biological risk can help guide both analytical monitoring and manufacturing controls [5,7].

The relationship between **medicinal chemistry and impurity control** is also significant. Changes introduced during molecular synthesis can influence the formation of side products and degradation pathways. Medicinal chemists can contribute to impurity reduction by selecting appropriate synthetic routes, reagents, protecting groups, reaction conditions, and purification strategies. Thus, impurity control should begin during chemical development rather than being treated solely as a final quality-control activity.

Analytical chemistry provides the tools needed to verify whether these strategies are effective. A well-designed analytical method should be capable of separating the active pharmaceutical ingredient from relevant impurities and degradation products. Method specificity, sensitivity, accuracy, and robustness are particularly important when low-level impurities must be monitored. Reliable analytical procedures therefore provide a foundation for informed pharmaceutical quality decisions [3,4].

Structure elucidation is another important component of impurity assessment. Detection of an unknown chromatographic peak may indicate the presence of an impurity, but understanding its significance requires determination of its chemical identity. Mass spectrometry can provide molecular-weight and fragmentation information, while spectroscopic techniques can provide additional structural evidence. Combining complementary analytical approaches can increase confidence in impurity identification [3,4].

Impurity profiling can also contribute to **process understanding**. Changes in impurity patterns may reveal variations in raw materials, reaction conditions, purification performance, or storage conditions. Monitoring impurity profiles over time can therefore provide useful information for process optimization and quality assurance. In this sense, impurities can serve as chemical indicators of manufacturing and product behavior rather than merely being undesirable contaminants.

A broader approach to pharmaceutical quality should therefore consider impurities as **critical quality attributes** when their presence has a meaningful influence on product safety, efficacy, stability, or consistency. This requires a science-based assessment that considers the origin, chemical structure, concentration, potential toxicity, and behavior of individual impurities rather than relying exclusively on numerical limits.

The growing complexity of modern pharmaceutical products makes impurity assessment increasingly important. New synthetic strategies, complex molecular structures, advanced formulations, and increasingly sensitive analytical technologies can reveal chemical species that were previously difficult to detect. This creates both opportunities and challenges: improved detection provides greater knowledge of product composition, but it also requires careful interpretation to distinguish analytically detectable components from impurities of genuine pharmaceutical significance.

Greater collaboration among medicinal chemists, analytical chemists, formulation scientists, toxicologists,

and manufacturing specialists can strengthen impurity management. Understanding impurity formation at the molecular level can help connect chemical synthesis with analytical monitoring and safety assessment. Such integration can support more efficient development strategies while maintaining appropriate standards of pharmaceutical quality.

Ultimately, impurity control should not be viewed as an isolated regulatory or analytical exercise. It is closely connected to chemical design, manufacturing science, analytical characterization, stability, and patient safety. Moving from simple impurity removal toward a deeper understanding of impurity formation and significance can provide a more rational approach to pharmaceutical development.

Conclusion

Pharmaceutical impurities are more than unwanted chemical components; they can provide important information about drug synthesis, stability, manufacturing processes, and product quality. Modern analytical techniques enable increasingly sensitive detection and structural characterization, while medicinal chemistry and process development can help minimize their formation. A scientifically informed approach should consider not only the concentration of an impurity but also its chemical identity, origin, stability, exposure, and potential biological significance. Integrating impurity assessment into pharmaceutical development from an early stage can improve process control, analytical confidence, product consistency,

and patient safety. Treating relevant impurities as critical quality considerations therefore represents an important step toward more robust and reliable pharmaceutical development.

References

1. Alsante KM, Hatajik TD, Baertschi SW, Reed RA (2001) Isolation and identification of pharmaceutical impurities and degradants. *Adv Drug Deliv Rev* 52(3): 207-258.
2. Blessy M, Patel RD, Prajapati PN, Agrawal YK (2014) Development of forced degradation and stability indicating studies of drugs A review. *J Pharm Anal* 4(3): 159-165.
3. Gorog S (2006) Identification and determination of impurities in drugs. *Trends Anal Chem* 25(8): 755-757.
4. Gorog S (2005) The importance and the challenges of impurity profiling in modern pharmaceutical analysis. *Trends Anal Chem* 24(7): 644-651.
5. Elder DP, Snodin DJ (2009) A review of the genotoxicity of marketed pharmaceuticals. *Mutat Res* 681(2-3): 200-218.
6. Waterman KC, Adami RC (2005) Accelerated aging: prediction of chemical stability of pharmaceuticals. *Int J Pharm* 293(1-2): 101-125.
7. Kalgutkar AS, Didiuk MT (2009) An overview of the genotoxicity of pharmaceutical impurities. *Curr Opin Drug Discov Devel* 12(1): 106-117.